rate reiter unit state go sg websit
stock offer everyth
upsid tp
nc chang
think abbv therapeut exposur make larg cap pharma
stock least like hit price pressur us addit
expect market lead posit immuno-inflamm blood
cancer deliv best class growth cash return
sharehold although comfort best-perform
larg cap pharma stock last month still cheap
linger misconcept over-reli humira howev
expect rerat driven investor increas convict
abil increasingli credibl manag team diversifi
stock market fulli discount long rang risk-adjust non
humira revenu tp would potenti rise
one trick poni mani investor met last six month
appear believ humira settlement us simpli delay inevit cliff fall
view overlook potenti exist late-stag pipelin
diversifi mitig risk prolong slump sale ep next
decad coverag univers far greatest beneficiari us tax reform
said prospect materi cash return sharehold appar well
given manag high convict in-hous pipelin
calcul target price alway tp base straight averag
ev/ebita multipl dcf impli pe
premium global pharma coverag univers sector
continu expect deliv high-qual sale ep growth rate
consist well sector averag forecast period
dividend estim tp impli tsr buy
risk tp rate recommend would downsid
group ebit forecast humira annual us eros post biosimilar entri year
mid teen rather high singl digit magnitud downsid would
similar either risankizumab jak inhibitor fail commercialis
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
pipelin fail might cut dividend help fund major acquisit
creat via spin-out abbott lab pharma busi
humira treat autoimmun diseas rheumatoid arthriti account
abbv group revenu follow unsuccess attempt acquir shire buy
bought blood cancer specialist pharmacycl bid diversifi
away humira consensu forecast face biosimilar gener competit
addit inflamm cancer abbv key area therapeut
focu virolog women health result publish long rang
includ non-humira revenu forecast excess
product relev invest debat bn
invest debat
reason
via knoll acquisit
via pharmacycl acquisit
jv roch book
hous
licens boehring ingelheim
licens neurocrin bioscienc
reason
lack therapeut diversif
gener dividend buyback free cash flow return
next five year estim
 track record spent acquir us right imbruvica
 spent secur ex-u right
transform stori pipelin surpris upsid off-set gener
consensu estim top- bottom-lin growth sector averag
due impact humira eros
group sale sg estim comparison consensu
sale estim ahead consensu optimist
prospect base busi late stage pipelin tabl expect
greater upsid surpris ep expect deliv better oper leverag
tabl
non gaap ep sg estim comparison consensu
forecast deliv sale ep growth consist ahead sector averag
chart strong execut humira immune-inflamm
imbruvica blood cancer late stage pipelin particular risankizumab
treat immuno-inflamm investor gain greater convict abbv long
rang target non humira revenu excess growth
would even sector averag
use cash
shown left-hand chart forecast
cumul gener post-tax free cash roughli half return
sharehold via dividend buyback manag state major highli
unlik period need focu maximis valu
compani alreadi spent last two year cancer specialist pharmacycl
stemcentrx shown right-hand chart mean
attract incom stori global pharma coverag univers
rather provid exhaust list tabl describ key needle-mov
event stock next three year view import mileston
period phase data readout risankizumab imbruvica abt-
jak inhibitor venclexta
note studi highlight asterix event driven read date approxim
price-to-earnings rel world pharma
shown left-hand chart abbv price-to-earnings multipl expand month
follow spin-out abbott lab driven part better oper execut
howev multipl subsequ contract probabl due concern potenti
rang impact biosimilar competit humira insid outsid us
recent rerat driven settlement legal challeng
humira mean stock trade premium world pharma
index first time sinc left-hand chart howev view market
still undervalu compani futur growth prospect left-hand chart
percept still heavili reliant humira respect disagre
believ pipelin drive quicker diversif right-hand chart
sourc sale bn
shown right-hand chart forecast humira contribut group
revenu essenti halv ten year time despit fact estim
non-humira revenu well compani guidanc
premium/discount sector
assum premium sector averag account
sale ebita growth ultra lower tax rate
still assum wacc perpetu growth rate
alway tp base straight averag ev/ebita multipl
dcf impli pe premium global pharma coverag
univers sector continu expect deliv high-qual sale
ep growth rate consist well sector averag forecast
tabl model impact central scenario posit
neg take relev product current portfolio late-
stage pipelin help us calibr magnitud risk compani face
go forward use ebit analysi given long product cycl
pharmaceut industri forecast downsid risk ebit
estim upsid vs
sale varianc sourc upsid
ebit varianc sourc upsid downsid
summari financi statement except ep dp
product sold
equival
total liabil equiti
chang work capit
flow oper activ
purchas secur net
flow invest activ
net chang debt
purchas treasuri stock
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
sg cross asset research/equ balanc sheet cash flow estim number
abbvie-bul vs bear scenario potenti impact ebit
impact
impact
sale sale guidanc
eros
on-going trial success
on-going trial unsuccess
full approv indic current
full approv indic current
full approv indic current
full approv indic current
full approv indic current
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report justin smith
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan seoul warsaw
straight averag sotp base averag ev/ebita multipl dcf wacc termin growth
would downsid group ebit forecast humira annual us eros post biosimilar entri year mid-
teen rather high-singl digit magnitud downsid would similar either risankizumab jak inhibitor
fail commercialis pipelin fail might cut dividend help fund major acquisit
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag novarti financ sa bond issu senior
sg act co-manag novarti financ bond
